menu
    • menu
    [{"orgOrder":0,"company":"Hovione","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Modified Cyclodextrin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Hovione","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Hovione \/ Ligand","highestDevelopmentStatusID":"12","companyTruncated":"Hovione \/ Ligand"},{"orgOrder":0,"company":"Hovione","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Hovione","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Ointment","sponsorNew":"Hovione \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Hovione \/ Not Applicable"},{"orgOrder":0,"company":"Hovione","sponsor":"Ji Xing Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"JX08","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Hovione","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Hovione \/ Ji Xing Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hovione \/ Ji Xing Pharmaceuticals"},{"orgOrder":0,"company":"Hovione","sponsor":"Zerion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Beta-lactoglobulin","moa":"","graph1":"Technology","graph2":"Preclinical","graph3":"Hovione","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Hovione \/ Hovione","highestDevelopmentStatusID":"4","companyTruncated":"Hovione \/ Hovione"}]

    Find Clinical Drug Pipeline Developments & Deals by Hovione

    Menu

    Hovione

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hovione

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed

                            Hovione

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Beta-lactoglobulin

                            Therapeutic Area : Technology

                            Study Phase : Preclinical

                            Recipient : Zerion Pharma

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Zerion Pharma and Hovione Extend Partnership to Cover Use of The Dispersome® Technology Platform in Nutraceut...

                            Details : Under their collaboration, Hovione and Zerion will now upscale and develop commercial formulations of the beta-lactoglobulin or BLG using the Dispersome® platform and make Lacprodan products available for distribution by partners globally.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 23, 2022

                            Lead Product(s) : Beta-lactoglobulin

                            Therapeutic Area : Technology

                            Highest Development Status : Preclinical

                            Recipient : Zerion Pharma

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hovione

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed

                            Hovione

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JX08

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : Ji Xing Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Hovione and JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program

                            Details : Under the license agreement, JIXING will receive global rights to JX08 and lead the full life cycle of development from preclinical through commercialization.

                            Brand Name : JX08

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 09, 2022

                            Lead Product(s) : JX08

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : Ji Xing Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hovione

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed

                            Hovione

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Hovione Completes its Phase 2 Clinical Trial of the First Minocycline Ophthalmic

                            Details : This is the first dry eye therapy targeting MGD patients with ocular inflammation demonstrated by an MMP-9 based diagnostic and the first and only ophthalmic formulation of minocycline in clinical development, contingently named Meizuvo®.

                            Brand Name : HY02

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 17, 2021

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hovione

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed

                            Hovione

                            Portugal arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Modified Cyclodextrin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Ligand Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Hovione Announces Partnership to Support Manufacturing of Antiviral Veklury® for COVID-19

                            Details : The partnership aims to significantly ramp up the production output of Captisol®. Captisol®, a Ligand product and a chemically modified cyclodextrin proven to improve the solubility and stability of drugs.

                            Brand Name : Captisol

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 23, 2020

                            Lead Product(s) : Modified Cyclodextrin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Ligand Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth